Natco Pharma Surges on Dual Catalysts, Patent Risks Loom

Natco Pharma faces ongoing patent litigation with Novo Nordisk over Semaglutide rights that could impede market access for its CDSCO-approved generic version launching March 2026. Patent revocation suits against Novo Nordisk's patent rights create uncertainty, as adverse rulings would significantly limit Natco's ability to capitalize on the diabetes drug market opportunity. Competitors like Dr. Reddy's and Sun Pharma have already secured judicial permissions for exports, highlighting the litigation's impact on market positioning.